Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
Ensitrelvir may protect a range of individuals from COVID-19, including those at higher risk for severe disease. HealthDay News — For persons who are severe acute respiratory syndrome coronavirus-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results